Isoquinoline Compounds for Topical AhR Modulation in Skin Inflammation
Solution Overview
Problem
Current treatments for inflammatory diseases, particularly chronic inflammatory skin diseases, lack effective topical interventions that modulate Aryl hydrocarbon Receptor (AhR) pathways to address imbalances and reduce cytokine-mediated inflammation.
Innovation Solution
Development of isoquinoline compounds that bind and activate the AhR, providing a novel class of anti-inflammatory agents for topical treatment, including formulations for skin application, to modulate cytokine expression and treat conditions such as psoriasis and atopic dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current treatments for inflammatory diseases are used, then existing therapeutic options are available, but effective topical interventions that modulate AhR pathways are lacking
Solution Approach 1:
The patent segments the treatment approach by developing specific topical formulations containing isoquinoline compounds that selectively activate AhR pathways in skin tissues, separating this mechanism from systemic treatments and enabling targeted local therapy for inflammatory skin diseases
Solution Approach 2:
The patent changes the chemical parameter space by introducing isoquinoline compounds with specific molecular structures (Formula I variants) that have optimized affinity for AhR activation, thereby creating new therapeutic agents with enhanced pathway modulation capability compared to existing treatments
2Reliability
If isoquinoline compounds are developed to activate AhR, then novel anti-inflammatory agents are provided, but the complexity of the compound structure increases
Solution Approach 1:
The patent systematically varies molecular parameters of the isoquinoline core structure (substituents at different positions, ring modifications) to optimize AhR binding affinity and anti-inflammatory efficacy, balancing structural complexity with therapeutic reliability
Solution Approach 2:
The patent introduces specific functional groups and substituents at particular positions on the isoquinoline ring structure to enhance AhR interaction locally, rather than uniformly increasing complexity throughout the entire molecule
3Ease of operation
If topical formulations are developed for skin application, then localized treatment is achieved, but formulation complexity increases
Solution Approach 1:
The patent develops topical formulations in the form of creams, ointments, or gels that can be easily applied to skin surfaces, using conventional pharmaceutical vehicle systems rather than complex delivery devices, thereby maintaining ease of operation
Solution Approach 2:
The patent uses pharmaceutical excipients and vehicle components as intermediaries to solubilize and stabilize the isoquinoline compounds in topical formulations, simplifying the overall formulation complexity while enabling effective skin application
4Reliability
If AhR activation is used to reduce cytokine expression, then anti-inflammatory effects are achieved, but the mechanism requires novel compound classes
Solution Approach 1:
The patent modifies the chemical structure parameters of known isoquinoline compounds to optimize AhR binding characteristics and cytokine modulation efficacy, building upon existing chemical knowledge rather than requiring entirely novel compound classes
Solution Approach 2:
The patent performs preliminary structure-activity relationship studies and in vitro screening to identify promising isoquinoline variants before advancing to in vivo efficacy studies, streamlining the development process from compound identification to therapeutic validation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The isoquinoline compounds effectively reduce IL-17A expression, enhance skin barrier formation, and provide therapeutic benefits in inflammatory skin diseases by activating AhR, demonstrating efficacy in preclinical models.
Implementation Method 1
Compounds described herein bind and activates the Aryl hydrocarbon Receptor (AhR), providing a novel class of anti-inflammatory compounds with AhR-dependent cytokine modulation
Data Source
AI summary
The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.